Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 1 (1 Shares)  

Printer Friendly Page Save As Favorite View Favorites (# of views)   No comments
General News

Bone Drug/Cancer News Highlights Women's Risky Therapy Choices

By       Message Martha Rosenberg     Permalink
      (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; , Add Tags Add to My Group(s)

Must Read 1   News 1   Valuable 1  
View Ratings | Rate It Headlined to H3 12/15/09

Author 1353
Become a Fan
  (78 fans)
- Advertisement -

- Advertisement -

Ladies, Pick Your Cancer

Many women receiving menopausal treatments today are too young to remember the old American folk tune, There Was An Old Lady Who Swallowed A Fly even though the song could be written about them.

- Advertisement -

The old lady, swallows a spider to catch the fly--then a bird to catch the spider, then a cat to catch the bird ad infinitum--until she is a walking Noah's Ark and iatrogenic casualty.

For forty years women obligingly swallowed the "fly" of Premarin, a horse urine menopause drug manufactured by Wyeth (now Pfizer) until it was revealed to increase endometrial cancer in the 1970s.

But not to worry. Wyeth had a better drug, the notorious Prempro ("spider") which, by adding a progestin to the estrogen, reduced endometrial cancer while increasing the risk of breast, ovarian and lung cancers. Oops. Nor did the original endometrial cancer risk completely go away.

Once Prempro was found to cause cancer and greater difficulty in reading mammograms that would detect same, Selective Estrogen Receptor Modulators or SERMs surfaced (the "bird.")

SERMS like tamoxifen and Evista could help mammogram readability and prevent and/or treat breast cancer. Except they could contribute to endometrial and ovarian cancer. Anyone see where this is going?

No wonder when the news broke last week that bisphosphonate bone drugs like Fosamax and Boniva could reduce the incidence of breast cancer, women reacted with another American folkism: "Fool Me Twice, Shame on Me."

Sure the re-analysis of Women's Health Initiative data (WHI) by original author Rowan Chlebowski, MD, found women taking the bone drugs had 31 percent less invasive breast cancer after seven years. But the women on bisphosphonates in the paper presented at the Annual San Antonio Breast Cancer Symposium were also more likely to get noninvasive breast cancer called ductal carcinoma in situ (DCIS).

- Advertisement -

This is not the only example of the choice given to women of "trading" one cancer for another--some termed "good cancer"-- thanks to Wall Street wonder drugs that make women into lab animals. In fact within hours of the news, "Study Shows Merck's Fosamax May Fight Breast Cancer," appeared on

Next Page  1  |  2


- Advertisement -

Must Read 1   News 1   Valuable 1  
View Ratings | Rate It

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting
/* The Petition Site */
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
- Advertisement -

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too